Pay in 4 interest-free payments of $5.73 Learn more
Ships within 48 hours · Estimated delivery Nov 11 - Nov 16
Cork MJ, Danby SG, Vasilopoulos Y, Hadgraft J, Lane ME, Moustafa M, et al
The primary endpoint was change in HbA 1c (%-points) from baseline to week 40
(Maywood) 243 , 3444
Abstract The use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) is increasingly common due to dramatic improvement in clinical outcomes of metabolic conditions
Conducted between June 2011 and March 2013 at 191 sites in 27 countries in Europe, North America, South America, Asia, and Australia this was a randomised, placebo-controlled trial designed to evaluate the efficacy and safety of 3mg liraglutide 'injected subcutaneously once daily, as an adjunct to a reduced-calorie diet and increased physical activity, for weight management in overweight or obese adults who did not have diabetes at baseline.' A total of 3,731 individuals participated in the trial, of whom 2,487 were assigned to lifestyle intervention plus liraglutide and 1,244 to lifestyle intervention with a placebo
US$ 22.69
US$ 26.98
US$ 24.24
US$ 27.59
US$ 27.10
US$ 29.60
